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Introduction: Historically breast cancer surgery was associated
with significant psychosocial morbidity and suboptimal cosmetic
outcome. Recent emphasis on women’s quality of life following
breast cancer treatment has drawn attention to the importance
of aesthetic outcome and the potential benefits of immediate
breast reconstruction (IBR). Although breast conservation is the
ideal, more radical surgery is still indicated for approximately
one-third of patients. For these women, IBR could avert such mor-
bidity and improve aesthetic results. Our aim was to assess onco-
logical safety, morbidity and patient satisfaction after IBR.
Methods: A prospectively collected database of all breast cancer
patients who underwent IBR at a tertiary referral breast unit was
reviewed. Clinicopathological and operative data were obtained;
patients were reviewed clinically, and administered two validated
quality of life questionnaires following their treatment.
Results: Two hundred and fifty five patients underwent IBR fol-
lowing skin-sparing mastectomy over 61 months. Reconstruction
with autologous ipsilateral latissimus dorsi flap was most com-
monly performed (88%). After median follow-up of 36 months,
no patient had experienced local recurrence (0%), distant metas-
tases developed in 4.8% and mortality was 2.2%. Post-operative
morbidities included wound infection (11.9%), chronic pain
(1.8%), prosthesis removal/replacement (9.3%; 42.8% of whom
had radiotherapy) and fat necrosis (14.2%). Patient satisfaction
was comparable to a group of age-matched women (n = 160)
who underwent breast conserving surgery (p = 0.89).
Conclusions: IBR is a highly acceptable, desirable form of treat-
ment for women requiring mastectomy. With its low associated
morbidity, good oncological safety and high rates of patient satis-
faction, IBR is an appropriate recommendation for all women
requiring mastectomy.
doi:10.1016/j.ejcsup.2010.06.007
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Background: Although breast conserving therapy (BCT) is the
standard of care for early stage breast cancer, recent literature
suggests that contour deformities, breast asymmetry, and poor
esthetic outcomes are not uncommon.
Methods: We have performed transplantation of progenitor-
enriched adipose tissue (Cell-assisted lipotransfer; CAL) for man-
agement of contour deformities after BCT. In CAL, autologous adi-
pose-derived stem/stromal cells (ASCs) are used in combination
with lipoinjection. Adipose tissue was harvested from the abdo-
men, upper hip or thigh. A stromal vascular fraction containing
ASCs was freshly isolated from half of an aspirated fat sample and
attached to theotherhalf of aspirated fat sample. Thegraftmaterial
is injected into the subcutaneous layer and pectoralis muscles.
Results: Twenty-six patients underwent CAL. The volume of
injected fat was from 180 to 250 ml. In some patients who have
received radiotherapy, it seems to be a poor recipient bed for fat
grafting because of fibrosis, atrophy or retraction in these areas.
After performing single session, the panel judged contour
improvement to be good or very good in 13 patients, moderate
in 10 patients and poor in 3 patients. The previously irradiated
breast may require a multisession procedure for restoration of
the breast volume.
Conclusions: Breast reconstruction with lipoinjection has sev-
eral advantages such as lack of scarring in recipient and donor
sites. CAL is useful and effective option for management of con-
tour deformities after BCT.
doi:10.1016/j.ejcsup.2010.06.008
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Introduction: Treatment recommendations in breast reconstruc-
tion should encompass the assessment of both clinical outcomes
as well as patient reported outcomes (PROs) that include body
image and satisfaction with cosmetic appearance.1 The Body
Image Scale (BIS) has beenused to gauge the effects ofmastectomy
and breast reconstruction as well as study-specific questionnaires
(SSQ) that assess patient satisfaction with aesthetic appearance.
Methods: In a prospective study of women undergoing types of
Latissimus Dorsi (LD) breast reconstruction (±RT), the BIS and an
aesthetic satisfaction SSQ were administered up to 5 years after
surgery. Standardised 5 view photographs were taken and inde-
pendently scored using a 5-point Likert scale comprising a panel
of 3 HCPs. Spearmans correlation was used to test between PROs
and HCPs scoring of back symmetry and scar, satisfaction with
overall aesthetic appearance and overall outcome of the surgery.
Results: In 72 women (over 5 years) there was a significant cor-
relation between the PROs and the HCPs reporting of aesthetic
appearance (p = 0.001). The SSQ correlated significantly with BIS
(p < 0.001) at all time points up to 5 years. However, there was
no significant correlation between HCP assessments compared
with other PROs and BIS.
Conclusions: HCPs assessments of breast reconstruction out-
comes do not necessarily correlate with PROs and therefore can-
not be used exclusively in treatment recommendations regarding
the optimal types of breast reconstruction. The SSQ has been
shown to correlate with BIS1 and is of value in assessing PROs
until the introduction of a validated breast reconstruction-spe-
cific questionnaire.
Reference:
1. Amulticentre prospective longitudinal study establishing level II
evidence of HRQL after types of immediate LD breast
reconstruction. CancerResearch 2009;69(24):682s [abtr. no. 3106].
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